Teva Pharma (TEVA) Reports In-Line Q1 EPS on Light Revs

Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) reported Q1 EPS of $1.04, in-line with the analyst estimate of $1.04. Revenue for the quarter came in at $4.08 billion versus the consensus estimate of $4.25 billion.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• John Wiley & Sons, Inc. (WLYB) Tops Q4 EPS by 12c; Offers Outlook